EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting

Mike A Cornejo, Zachary V Samuels iD, Gina Dehlavi, Lukas Carter, Wei-Siang Mark Kao, Emilia Strugala, Brian M Zeglis iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Mike A Cornejo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States. Hauptthemen laut MEDLINE: Copper Radioisotopes, Radiopharmaceuticals, Immunoconjugates, Theranostic Nanomedicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Allergy and Infectious Diseases, Division of Graduate Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo pretargeting offers a strategy to improve nuclear imaging and radiopharmaceutical therapy by increasing tumor-to-background activity concentration ratios and decreasing radiation burden to healthy tissues. One particularly promising approach to in vivo pretargeting is predicated on the inverse electron-demand Diels-Alder (IEDDA) ligation between tetrazine (Tz)-based radioligands and trans-cyclooctene (TCO)-bearing immunoconjugates. Not surprisingly, the performance of such systems is highly dependent upon the pharmacokinetic profiles of the small molecule radioligands. Herein, we report the synthesis and characterization of a trio of sarcophagine-bearing tetrazines─SarAr-Tz, SarAr-PEG5-Tz, and SarAr-PEG10-Tz─as well as their radiolabeling with copper-64 (64Cu, t1/2 ∼ 12.7 h), a positron-emitting radioisotope of copper. These radioligands were paired with a TCO-bearing variant of the A33 antigen-targeting antibody huA33 (i.e., huA33-TCO) for pretargeted immunoPET in a murine model of colorectal cancer, revealing that all three produced images with excellent tumor-to-background contrast, but [64Cu]Cu-SarAr-PEG10-Tz yielded the best tumor-to-tissue activity concentration ratios. In light of its superior performance, SarAr-PEG10-Tz was subsequently radiolabeled with copper-67 (67Cu, t1/2 ∼ 61.8 h), a β--emitting radioisotope of copper, to produce [67Cu]Cu-SarAr-PEG10-Tz. This radioligand was then paired with huA33-TCO for in vivo biodistribution and longitudinal therapy studies, ultimately revealing that pretargeted radioimmunotherapy with [67Cu]Cu-SarAr-PEG10-Tz exhibits promising efficacy and safety in a murine model of colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Copper RadioisotopesRadiopharmaceuticalsImmunoconjugatesTheranostic NanomedicineColorectal NeoplasmsAnimalsMiceHumansTissue DistributionPositron-Emission TomographyCell Line, TumorFemaleCyclooctanesRadioimmunotherapyPolyethylene GlycolsHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

PEGylationPETcopper-64copper-67multistep targetingpositron emission tomographypretargeted radioimmunotherapypretargetingradiocopperradioimmunotherapyradiopharmaceutical therapysarcophaginetargeted radionuclide therapy

Substanzen

Copper RadioisotopesRadiopharmaceuticalsCopper-64CyclooctanesImmunoconjugatesPolyethylene GlycolsHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Chemistry, Hunter College, The City University of New York, New York, New York 10021, United States.
  • Ph.D. Program in Chemistry, Graduate Center of the City University of New York, New York, New York 10016, United States.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Ph. D.Program in Biochemistry, Graduate Center of the City University of New York, New York, New York 10016, United States.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
  • Department of Radiology, Weill Cornell Medical College, New York, New York 10021, United States.

ORCID-Profile: Zachary V Samuels, Brian M Zeglis

Förderung

  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Division of Graduate Education
  • Center for Cancer Research

Zitieren

APA

Cornejo, M. A., Samuels, Z. V., Dehlavi, G., Carter, L., Kao, W. M., Strugala, E., & Zeglis, B. M. (2026). Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01512

Vancouver

Cornejo MA, Samuels ZV, Dehlavi G, Carter L, Kao WM, Strugala E, et al. Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01512

BibTeX
@article{Cornejo2026,
  author = {Cornejo, Mike A and Samuels, Zachary V and Dehlavi, Gina and Carter, Lukas and Kao, Wei-Siang Mark and Strugala, Emilia and Zeglis, Brian M},
  title = {Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01512}
}
Kostenlos starten →